AIDASH
The majority of businesses will struggle to meet net-zero goals without the use of carbon credits, but a lack of trust in the tool is stalling uptake and pushing corporate net-zero plans off track. This is one of the striking findings from a global survey of over 500 senior sustainability officers, commissioned by AiDash, a leading provider of vegetation management and other satellite- and AI-powered operations, maintenance, and sustainability solutions.
The ‘Carbon Offsetting in 2023’ study shows sustainability and carbon management are now mainstream concerns, with 97% of businesses including them in investment decisions, 79% of CSO’s already accountable to their boards or the public, 98% doing more than legally required to reduce emissions and 56% of businesses committed to net-zero targets on or before 2030.
However, over half of businesses (56%) do not have operational control over the majority of their greenhouse gas (GHG) emissions and nearly half (43%) use carbon offsets for hard-to-reduce GHG emissions alongside direct measures. As a result, many businesses cannot meet net-zero targets without the use of carbon credits.
Despite this critical need, the survey revealed a major lack of trust in carbon offsetting, with 41% of CSOs stating they do not use carbon credits as they do not adequately trust them. This comes at a time when many carbon offsetting projects are being shown to be inconsistently measured, inadequately monitored, and frequently failing to prove they are based on additional carbon captured.
Another revelation is the inconsistency in validation methods for carbon credits. 4% do not validate credits at all, 35% only buy from government or voluntary certified schemes, 43% are exploring working with credit rating agencies, 35% undertake their own validation or third-party due diligence and 41% use a combination of these methods. This lack of uniformity raises doubts surrounding the accuracy and comparability of corporate sustainability measurements.
With 89% of CSOs confirming they use KPI metrics to track the progress of their sustainability plans, it is essential that those metrics are watertight. However, the three biggest challenges to meeting net-zero goals are all data related:
- Collating reference data such as regional electricity and airline emissions factors (26%)
- Lack of common reporting frameworks (19%)
- Difficulty collating internal information (18%)
“Rather than waiting for governments to agree to regional or global frameworks, businesses are forging forward independently, making ambitious environmental commitments,” says Abhishek Vinod Singh, CEO, AiDash. “The intent and action is there but what these businesses desperately need is an organizational tool they can trust to accurately measure, monitor, track and validate the progress of their sustainability plans on their journey to net-zero.”
Carbon offsetting was not the only hot topic of the survey. It also revealed that CSOs are turning their eyes towards biodiversity. While only 24% currently include biodiversity impact in their sustainability strategies, 66% already have a role dedicated to biodiversity, with a substantial proportion intending to introduce one in the next two years. However, as it stands, legacy approaches to measuring biodiversity could hamper progress.
“Advances in satellite and AI technology can solve the vast majority of issues businesses are having collecting, analyzing and verifying their sustainability data,” continues Singh. “Our carbon solution not only provides measurements that meet carbon credit standards, but also continuous evidence to prove that credits are based on additional carbon captured and that carbon remains permanently in the ground, which is crucial for credible ESG reporting. By supporting how businesses apply carbon offsetting to their own land, we can save them up to 90% when compared with buying the equivalent from an escalating carbon credit market.
“For biodiversity, our solution can measure a host of complex environmental assets, allowing businesses to enhance natural capital metrics such as pollination, recreational benefits, and the value of food production. By analyzing 1,000s of sites in a matter of weeks, and utilizing one ecologist to verify the data captured, the AiDash solution can reduce biodiversity management operational expenditure by up to 75%, helping businesses adhere to impending legislation in the US, Europe, and UK.”
To download the complete survey results, visit https://www.aidash.com/resource/carbon-offsets-report-2023/
About AiDash
AiDash is an AI-first vertical SaaS company on a mission to transform operations, maintenance, and sustainability in industries with geographically distributed assets by using satellites and AI at scale. With access to a continual, near real-time stream of critical data, utilities, energy, mining, and other core industries can make more informed decisions and build optimized long-term plans, all while reducing costs, improving reliability, and achieving sustainability goals. To learn more about how AiDash is helping core industries become more resilient, efficient, and sustainable, visit www.aidash.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
